|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7645801||MYLAN SPECIALITY LP||Reduced irritant enema for treatment of inflammatory bowel disease (IBD)|| |
(3 years from now)
Rowasa is owned by Mylan Speciality Lp.
Rowasa contains Mesalamine.
Rowasa has a total of 1 drug patent out of which 0 drug patents have expired.
Rowasa was authorised for market use on 24 December, 1987.
Rowasa is available in enema;rectal dosage forms.
The generics of Rowasa are possible to be released after 24 July, 2027.
Market Authorisation Date: 24 December, 1987
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic